Electrophysiologic study-guided amiodarone for sustained ventricular tachyarrhythmias associated with structural heart diseases

Circulation Journal

Volumn 72, Issue 1, 2008, Pages 88-93

  Aiba, Takeshi ^a   Yamagata, Kenichiro ^a   Shimizu, Wataru ^a   Taguchi, Atsushi ^a   Satomi, Kazuhiro ^a   Noda, Takashi ^a   Okamura, Hideo ^a   Suyama, Kazuhiro ^a   Aihara, Naohiko ^a   Kamakura, Shiro ^a   Kurita, Takashi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Amiodarone; Electrophysiologic study; Holter monitoring; Ventricular fibrillation; Ventricular tachycardia

Indexed keywords

AMIODARONE;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DEATH; ELECTROCARDIOGRAPHY; HEART FUNCTION TEST; HEART STROKE VOLUME; MIDDLE AGED;

AGED; AMIODARONE; DEATH; ELECTROCARDIOGRAPHY, AMBULATORY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 39849089361     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.88     Document Type: Article

References (26)

1. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96: 2823-2829.
2. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025-2034.
3. Investigators ATM-A. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
4. Aiba T, Kurita T, Taguchi A, Shimizu W, Suyama K, Aihara N, et al. Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrythmia and structural heart disease. Circ J 2002; 66: 367-371.
5. Kadish AH, Buxton AE, Waxman HL, Flores B, Josephson ME, Marchlinski FE. Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy. J Am Coll Cardiol 1987; 10: 90-96.
6. Veltri EP, Reid PR, Platia EV, Griffith LS. Amiodarone in the treatment of life-threatening ventricular tachycardia: Role of Holter monitoring in predicting long-term clinical efficacy. J Am Coll Cardiol 1985; 6: 806-813.
7. Zhu J, Haines DE, Lerman BB, DiMarco JP. Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. Circulation 1987; 76: 802-809.
8. Greenspon AJ, Volosin KJ, Greenberg RM, Jefferies L, Rotmensch HH. Amiodarone therapy: Role of early and late electrophysiologic studies. J Am Coll Cardiol 1988; 11: 117-123.
9. Yuge M, Niwano S, Moriguchi M, Sasaki T, Hirasawa S, Imaki R, et al. Clinical significance of the electrophysiologic study (EPS)-guided therapy for the secondary prevention of ventricular tachycardia. Circ J 2006; 70: 268-272.
10. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-1890.
11. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.
12. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754.
13. Schlapfer J, Rapp F, Kappenberger L, Fromer M. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: Results of long-term follow-up. J Am Coll Cardiol 2002; 39: 1813-1819.
14. Kurita T, Mitamura H, Aizawa Y, Nitta T, Aonuma K, Tsuboi N, et al. Japanese randomized trial for investigation of a combined therapy of amiodarone and implantable cardioverter defibrillator in patients with ventricular tachycardia and fibrillation: The Nippon ICD Plus Pharmacologic Option Necessity study design. Circ J 2006; 70: 316-320.
15. Satomi K, Kurita T, Takatsuki S, Yokoyama Y, Chinushi M, Tsuboi N, et al. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias. Circ J 2006; 70: 977-984.
16. Domanski MJ, Sakseena S, Epstein AE, Hallstrom AP, Brodsky MA, Kim S, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias: AVID Investigators: Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34: 1090-1095.
17. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study; Cardiac Arrest Study Hamburg; Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.
18. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: The Canadian Implantable Defibrillator Study. Circulation 2000; 101: 1660-1664.
19. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
20. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias: Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329: 452-458.
21. Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, Rotmensch H, et al. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 1985; 55: 367-371.
22. McGovern B, Garan H, Malacoff RF, DiMarco JP, Grant G, Sellers TD, et al. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 1984; 53: 1558-1563.
23. Nasir N Jr, Doyle TK, Wheeler SH, Pacifico A. Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol 1994; 73: 554-558.
24. Olson PJ, Woelfel A, Simpson RJ Jr, Foster JR. Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1993; 71: 823-826.
25. Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998; 32: 739-745.
26. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC Study: A randomized trial. JAMA 2006; 295: 165-171.